OUR TECHNOLOGY

POZ™ polymers may be synthesized in different architectures to match each therapeutic agent and its unique applications. The platform allows for half-life extension of proteins, flexibility in terms of drug attachment and release, and drug targeting to unique receptors and antigens on the surface of cancer cells.

HOW IT WORKS

Our POZ™ drug delivery platform is based on a water-soluble, low-viscosity polymer called poly(2-oxazoline) that is synthesized from readily available and safe starting materials. During the synthesis steps, a predictable amount of drug may be incorporated on the backbone of the polymer using pendent alkyne groups and metal catalyzed “click chemistry”. The technology is not limited to pendent POZ – linear POZ can also be applied to proteins, aptamers and other classes of molecules where extended plasma half-life is desired.

For more information, click here.

POZ™ versus PEG

POZ™ is wholly distinct with important advantages compared to PEG.

DESIRED POLYMER CHARACTERISTIC COMMERCIAL BENEFIT POZ™ PEG
Limited cellular uptake in non-target tissues Potential for improved safety Blue Check Concentrates in renal epithelium and multiple tissues (liver, bone marrow, spleen)
Non-immunogenic Improved safety may minimize allergic reactions and attenuation of response for chronic treatments Blue Check No. PEG is immunogenic. Approximately 25% of the population has demonstrated pre-formed antibodies to PEG.
Ability to increase drug payload and control rates of release Improved efficacy and compliance via less frequent dosing Blue Check Limited
Ability to target cells Potential to increase efficacy while reducing side effects Blue Check Challenging chemistry makes this more difficult to achieve
Low viscosity Easier preparation and administration to patients Blue Check No
Ease of synthesis Faster and safer drug synthesis may prove more economical Blue Check No. Requires explosive starting materials
Stability (storage and reconstitution) Less waste Blue Check BHT required to prevent oxidization
Strong IP Broad market exclusivity Blue Check Crowded patent estate
Ability to attach different drug classes Provides broader optimization for therapeutic candidates Blue Check Blue Check
Renal clearance Does not undergo metabolism in the body and is excreted unchanged Blue Check Blue Check

PATENTS

Serina therapeutics has a robust patent estate that includes twelve issued patents worldwide and twenty-four patents pending.

PUBLICATIONS

Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon
Publication Icon